Whole-Body MRI
WB-MRI
Whole-body MRI (WB-MRI) acquires MRI images from the top of the skull to the feet in a single session using a moving table and multiple overlapping body stations. No radiation, no contrast required in most protocols. Diffusion-weighted imaging (DWI) — which highlights tissues with high cellular density — allows WB-MRI to detect cancer deposits throughout the bone marrow, soft tissues, and lymph nodes. WB-MRI has replaced skeletal surveys for myeloma staging (NICE 2016), outperforms PET-CT for bone marrow disease in lymphoma, and is increasingly used for oligometastatic prostate cancer staging.
What It Shows
- Bone marrow infiltration — diffuse or focal disease in myeloma, lymphoma, leukaemia
- Skeletal metastases — earlier detection than bone scan, superior to CT for marrow disease
- Soft-tissue metastases, lymph nodes, and peritoneal disease
- Whole-body DWI map — highlights all sites of cellular tumour activity simultaneously
- Oligometastatic cancer staging — identifies number and location of all metastatic sites
- Spinal cord compression — full spinal assessment in one study
- Response to systemic therapy — marrow reconversion after myeloma treatment
How It Works
The patient lies supine on an MRI table. Multiple overlapping body 'stations' are acquired sequentially (skull base, neck/chest, abdomen, pelvis, thighs, legs) using standardised sequences: T1-weighted (anatomy), STIR/T2-fat-suppressed (oedema and lesions), and DWI (cellular density). The table moves between stations. Total acquisition time is 45–90 minutes. Images from all stations are automatically stitched together to form a single head-to-toe composite. A radiologist reviews the coronal T1, STIR, and DWI maps together.
Cancer Types
When Is It Used
- Myeloma staging and response assessment (IMWG criteria)
- Prostate cancer oligometastatic staging for metastasis-directed therapy planning
- Lymphoma bone marrow assessment (replacing trephine biopsy in some guidelines)
- Paediatric cancer staging where radiation minimisation is paramount
- Any staging scenario where radiation-free whole-body assessment is preferred
Evidence Summary
WB-MRI evidence is strongest in myeloma. The MYELOMA-XI trial demonstrated WB-MRI superior to skeletal survey for detecting bone disease. NICE (NG35, 2016) recommended WB-MRI as the preferred imaging for myeloma staging — replacing skeletal surveys. A 2020 meta-analysis showed WB-MRI sensitivity 91%, specificity 92% for myeloma bone lesions vs 57%, 97% for skeletal survey. In oligometastatic prostate cancer, WB-MRI detects 24% more lesions than CT + bone scan (STOMP trial pre-imaging data). Evidence for WB-MRI in other cancer types is growing but not yet at guideline-level in most indications. Main limitation is scan duration (45–90 min) and availability.
Preparation & What to Expect
Remove all metal objects. Declare implants and metallic devices. No fasting required for standard WB-MRI without contrast. Wear comfortable clothing. Be prepared for 60–90 minutes inside the scanner — some centres offer headphones and music. Patients must be able to lie still — sedation rarely needed.
Limitations
- Long scan duration — 45–90 min is uncomfortable for patients with pain or poor mobility
- Standard MRI contraindications apply (pacemakers, certain implants, severe claustrophobia)
- Limited availability outside specialist cancer centres
- Not optimal for lung parenchyma — CT remains superior for pulmonary metastases
- DWI can show false positives from inflammatory nodes, bowel, and physiological marrow activity
Safety & Cautions
- No radiation — safe for repeated use, appropriate for young patients and those requiring long-term monitoring
- Standard MRI safety contraindications apply — metal screening mandatory
- Requires specialist reporting — WB-MRI DWI interpretation requires specific training
Related Imaging Modalities
Informational only. Not medical advice. Always consult your oncologist or radiologist before any imaging procedure.